IPO: Pentixapharm now in the Prime Standard

The biopharmaceutical company from Würzburg, a spin-off of Eckert & Ziegler, was issued at 5.10 euros. 
 

3. October 2024. FRANKFURT (Börse Frankfurt). Pentixapharm Holding AG (DE000A40AEG0) has been listed in the Prime Standard of the Frankfurt Stock Exchange since today. The first price of the share was 5.10 euros. Previously, the security could be subscribed via the stock exchange.

BankM acted as Global Coordinator and Bookrunner for the IPO and as Designated Sponsor in Xetra trading. The specialist on the Frankfurt Stock Exchange is Wolfgang Steubing.

Pentixapharm Holding AG was founded in 2024 to absorb all shares held in Pentixapharm AG in the course of the spin-off from the parent company Eckert & Ziegler SE. Founded in Würzburg in 2019, Pentixapharm is a biopharmaceutical company that produces radiopharmaceuticals for the diagnosis and treatment of various diseases, primarily cancer and inflammatory diseases.

3. October 2024, © Deutsche Börse AG